Blockade of interleukin 6 signaling induces marked neutropenia in patients with rheumatoid arthritis.
Nakamura
Ichiro
I
Omata
Yasunori
Y
Naito
Masashi
M
Ito
Katsumi
K
D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D002634:Chemotaxis, Leukocyte / Q000187:drug effects / Q000276:immunology; D006801:Humans; D007108:Immune Tolerance / Q000187:drug effects / Q000276:immunology; D007166:Immunosuppressive Agents / Q000009:adverse effects; D015850:Interleukin-6 / Q000378:metabolism*; D007958:Leukocyte Count; D009503:Neutropenia / Q000139:chemically induced* / Q000276:immunology / Q000503:physiopathology; D009504:Neutrophils / Q000187:drug effects / Q000276:immunology; D019947:Receptors, Interleukin-6 / Q000037:antagonists & inhibitors* / Q000276:immunology / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects / Q000276:immunology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007166:Immunosuppressive Agents; D015850:Interleukin-6; D019947:Receptors, Interleukin-6; C502936:tocilizumab